Gynecologic oncology specialist. Passionate about women receiving individualized #GynOnc care within a welcoming environment.
Houston, TX
Joined April 2015
- Tweets968
- Following400
- Followers544
- Likes1.1K
Alpa Nick, M.D., M.S. retweeted
Most uterine carcinosarcomas have detectable TROP2 expression. In an innovative study by @saramoufarrij1 and team, organoid models showed encouraging response to TROP2 targeted antibody drug conjugate sacituzumab govitecan. @TeamOvary_MSK @TeamEndo_MSK
pubmed.ncbi.nlm.nih.gov/4034…
Alpa Nick, M.D., M.S. retweeted
This is Jana and Dr. @AlpaNick and their precious moment of Ovarcoming Together! 👏
See you all in your best PEARLS as we celebrate our Ovarcomers and Healthcare Heroes on May 17 with @shannonmiller96 as our Guest Extraordinaire! 👏
Keep inspiring, keep Ovarcoming! 🩵 #Ovare25
Alpa Nick, M.D., M.S. retweeted
🙌Azenosertib (WEE1i) has high activity in CCNE1 positive recurrent #ovariancancer - 👏👏👏design trials based on the right science and you get great results!!!
Incredible durable response - 34.9% in IHC positive tumors!
@GOG #gyncsm #SGOMtg #SGO2025
Alpa Nick, M.D., M.S. retweeted
🤩TROP2 ADC DB-1305 #Antibodydrugconjugate is very active in highly pretreated recurrent #ovariancancer!!
41% durable response rate
(7.3 mo DOR)
👏This agent is moving into phase 3 studies!!
#SGOMtg #SGO2025 #gyncsm
Alpa Nick, M.D., M.S. retweeted
🔥🔥🔥🔥TUBA-WISP II with amazing enrollment and the start of exciting and interesting data for high risk patients. Thank you Dr. Gootzen and the whole team! @SGO_org @GYNCancer #SGOMtg #SGO2025
Alpa Nick, M.D., M.S. retweeted
The use of avutometinib plus defactinib exceeded the response threshold and will advance to stage 2, for patients with advanced or recurrent mesonephric or mesonephric-like gynecologic cancer. #gyncsm #SGO25 | @SGO_org
cancernetwork.com/view/avuto…
Alpa Nick, M.D., M.S. retweeted
Great question - @rne_md said it best - "🎶 Tell me Why?? 🎶". Does #immunotherapy provide better long term outcomes and adverse event profile compared to progesterone or surgery? #SGOMtg #SGO2025 #gyncsm
This window of opportunity trial demonstrated an 80% complete response rate to neoadjuvant ICI in resectable dMMR endometrial cancer! Could this be an emerging option for fertility-sparing or medically frail patients? #SGO2025
Alpa Nick, M.D., M.S. retweeted
Congratulations @JudeNawlo on evaluating post-EWOC practice patterns in elderly cohort #ovarinacancer pts! Pts w single agent carbo had worst outcomes- impt@to use platinum doublet when feasible. @SGO_org @GOG @IGCSociety @gyncsm
Alpa Nick, M.D., M.S. retweeted
Had a great week in Biloxi, MS, the boys were able to go 3-1. Can’t wait for the rest of the season with this team!
Stats:
.500 (4-8) 2B, 3 RBI, 2 R, 2 SB, BB
1 2/3 innings 0H 0BB 0R 1K
@JulioBorbon20 @SBS_Athletics @PBRGowins @Texas_PG @PrepBaseball_TX @CoachCKirby2
Alpa Nick, M.D., M.S. retweeted
Omitting full pelvic lymphadenectomy did not negatively impact survival in early stage #cervicalcancer
🤨Unclear why there was higher recurrence in the pelvic LND group vs pts that underwent sentinel lymph node biopsy #SGOMtg #gyncsm #SGO2025
Alpa Nick, M.D., M.S. retweeted
Intriguing data for neoadjuvant #immunotherapy in resectable MMRd #endometrialcancer - high pathologic response rate but be careful of small n!!!
Looking forward to C93 (pembrolizumab) and Domenica (dostarlimab) study results in advanced and recurrent disease
#SGOMtg #gyncam
Alpa Nick, M.D., M.S. retweeted
Exciting Phase II data using Lenvatinib and Cadonilimab in adv/recur #endometrialcancer yielded 43% ORR and 93% disease control rate #SGOMtg #SGO2025
Alpa Nick, M.D., M.S. retweeted
👀High detection rate of ctDNA at baseline in the DUO-E study of olaparib and duralumab in #endometrialcancer
🧐Exploratory analyses suggest biggest benefit to combo in ctDNA positive disease - need to prospectively study this group!
#SGOMtg #SGO2025 #gyncsm
Alpa Nick, M.D., M.S. retweeted
Expanded data on Keynote A18 @SGO_org from Dr Duska showed continued benefit of addition of Pembro to CRT in #cervicalcancer with improved PFS and OS and 33% reduction of death. #SGOMtg #SGO2025 @amandanfader
Alpa Nick, M.D., M.S. retweeted
Expanded results by Dr Moore from DUO-E evaluating biomarkers and ctDNA in MMR-proficient #endometrial cancer showing subgroups who may benefit from adding Olaparib to CP + Durvalumab. #SGOMtg #SGO2025 @ShannonWestin
Opinion | Independent Surgeons Are Disappearing. Here's Why That Matters. medpagetoday.com/opinion/sec…
Alpa Nick, M.D., M.S. retweeted
Most viewed in the last 7 days from @JAMAOnc:
In a study of over 4,500 cancer patients, those who quit smoking within 6 months of diagnosis through a cessation program showed the greatest survival benefit.
ja.ma/3UHnBri
Alpa Nick, M.D., M.S. retweeted
What a memorable and meaningful Book Launch event honoring our Ovarcomers and Caregivers, complete with reading and mingling. Thank you Dr. @AlpaNick for hosting and to all Physicians who attended to support their patients! 🙏 THIS is how #WeOvarcome! 🩵 #BookLaunch #Ovarcoming
Alpa Nick, M.D., M.S. retweeted
Our memoirs of love, support, inspiration and encouragement by our Ovarcomers, will be out soon - our book OVARCOMING is launching soon! Thank you to ALL attending and supporting this memorable event tomorrow! #Grateful and thankful, this is how #WeOvarcome! 🩵 #BookLaunch
Alpa Nick, M.D., M.S. retweeted
Reposting - new guidelines for pancreatic screening in setting of ATM and BRCAmut. We see a lot of these in gyn cancers and need to program this into our algorithms (along with low dose lung cancer screening for those at risk but that is another thread....)
New recommendation for annual pancreatic cancer screening for people >50 years old with pathogenic ATM and BRCA mutations.
#bcsm
#gyncsm
#survivorship
#BRCA
#ATM